Looxid Labs

Looxid Labs operates at the intersection of neuroscience, wearable hardware, AI, and digital health. Its stated approach combines EEG and other biometric signals with machine-learning analysis, while its product portfolio spans a lightweight two-channel EEG device (Link Band 2.0), meditation support (Mind Breeze), and focus feedback (Focus Mate). That mix gives the company a broader application surface than a single-purpose meditation app, but also means its commercial position depends on proving value across distinct use cases and customer groups. Earlier work on an eye-brain VR interface and the Lucy assistive communication project points to an additional accessibility and immersive-computing direction. Relevant competitive dimensions include signal quality, comfort and usability of wearable hardware, validity of cognitive insights, and the ability to turn measurements into useful interventions.

Looxid Labs was founded in 2015 and developed through several early financing stages: a $100,000 pre-seed round in February 2015, a $750,000 seed round in September 2016, a second seed entry in January 2017 with no disclosed amount, and a $4 million Series A in November 2018. The disclosed round amounts add to the stated total of $4.85 million. Product direction appears to have broadened over time from an eye-brain VR headset and analytics toward assistive communication with Lucy and, in the listed portfolio, everyday EEG applications for focus, meditation, and cognitive analysis. Patent application publications in 2021 and 2022 indicate continued work on cognitive activity, testing, and preference-related methods, though applications alone do not establish commercial deployment. The company is marked active and has an employee-size band of 1–10, but the listed employee roles have older start dates. Current hiring momentum and recent revenue or adoption trends are not established.